First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

Gareth J. Morgan(Hywel Dda University Health Board), J. Anthony Child(University of Leeds), Walter M. Gregory(University of Leeds), Sylvia Feyler(Calderdale and Huddersfield NHS Foundation Trust), A. John Ashcroft(Mid Yorkshire Hospitals NHS Trust), Faith E. Davies(NYU Langone Health), Gordon Cook(University of Leeds), Mark T. Drayson(Institute of Immunology), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Sue Bell(University of Leeds), Huw Roddie(Western General Hospital), Jenny Byrne(Nottingham University Hospitals NHS Trust), Graham Jackson(Newcastle College), Claudius Rudin(Royal Devon and Exeter Hospital), Fiona Ross(University of Southampton), Alex J. Szubert(University of Leeds), Nuria Navarro-Coy(University of Leeds), Kim Cocks(University of Leeds)
The Lancet
December 1, 2010
10.1016/s0140-6736(10)62051-x
Cited by 571

Related Papers

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936
|Leukemia|2003|3k
The Global Syndemic of Obesity, Undernutrition, and Climate Change: The Lancet Commission report
|The Lancet|2019|3k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k